군발두통 역학 분석과 예측(2026년)

The Global Cluster Headache prevelance is expected to grow from USD 9.42 million patients in 2026 at a 2.3% CAGR to a market value of USD 11.53 million patients in 2035.

The global cluster headache epidemiology analysis market is becoming increasingly important as healthcare providers, pharmaceutical companies, research organizations, and policymakers seek comprehensive insights into disease prevalence, incidence, demographic distribution, diagnosis rates, disease burden, and long-term epidemiological trends. Epidemiological analysis serves as the foundation for drug development, clinical trial planning, healthcare resource allocation, and commercial forecasting by providing accurate estimates of patient populations and identifying unmet medical needs across different regions. As awareness of cluster headache improves and new therapeutic options emerge, epidemiological intelligence is playing an increasingly strategic role in supporting healthcare decision-making.

Cluster headache is a rare but highly debilitating primary headache disorder characterized by recurrent episodes of severe unilateral pain accompanied by autonomic symptoms. Although its prevalence is relatively low compared with migraine and other headache disorders, the condition imposes a substantial clinical, psychological, and socioeconomic burden due to its extreme pain intensity, frequent attacks, impaired quality of life, reduced work productivity, and increased healthcare utilization. Recent epidemiological research indicates that cluster headache affects approximately 0.1% of the global population, with episodic cluster headache representing the majority of diagnosed cases.

Advances in healthcare analytics, electronic health records, disease registries, artificial intelligence, and real-world evidence platforms are improving the quality and accuracy of epidemiological studies. These technologies enable researchers to evaluate prevalence, incidence, demographic characteristics, disease progression, treatment patterns, healthcare utilization, and regional variations more effectively. Epidemiological intelligence is increasingly supporting pharmaceutical pipeline development, health economics studies, reimbursement planning, and clinical trial recruitment.

Growing awareness among neurologists and headache specialists, improvements in diagnostic criteria, and increasing investment in neurological disorder research are expanding the diagnosed patient population worldwide. At the same time, ongoing efforts to reduce diagnostic delays and improve physician education are expected to strengthen epidemiological surveillance throughout the forecast period. As healthcare systems continue to prioritize rare neurological disorders, demand for comprehensive cluster headache epidemiology analysis is expected to increase steadily.

Market Drivers

Increasing Disease Awareness

Growing awareness among neurologists, primary care physicians, and headache specialists is improving recognition of cluster headache and reducing diagnostic delays.

Educational initiatives and updated clinical guidelines are contributing to more accurate epidemiological reporting and patient identification.

Expansion of Real-World Healthcare Data

Electronic health records, disease registries, insurance claims databases, and digital health platforms are strengthening epidemiological research.

Large healthcare datasets enable more accurate assessment of prevalence, incidence, healthcare utilization, and treatment outcomes.

Growing Investment in Neurology Research

Governments, academic institutions, pharmaceutical companies, and research organizations continue increasing investment in neurological disease research.

These investments improve epidemiological surveillance while supporting clinical development and healthcare planning.

Advances in Epidemiological Analytics

Artificial intelligence, predictive analytics, and real-world evidence technologies are improving patient identification and disease forecasting.

Advanced analytical tools enhance understanding of demographic trends, disease burden, and long-term epidemiological patterns.

Rising Demand for Rare Disease Intelligence

Increasing pharmaceutical interest in orphan neurological disorders has expanded the need for detailed patient population analysis.

Accurate epidemiological data supports market forecasting, clinical trial design, and commercialization strategies for emerging therapies.

Market Restraints

Underdiagnosis and Misdiagnosis

Cluster headache is frequently misdiagnosed because of symptom overlap with migraine, sinus disorders, and other headache conditions.

Delayed diagnosis continues to affect the accuracy of epidemiological estimates and patient identification.

Limited Epidemiological Data

Because cluster headache is a relatively rare neurological disorder, large-scale population studies remain limited in several regions.

Insufficient data availability may restrict comprehensive assessment of disease prevalence and regional variation.

Variability in Diagnostic Criteria

Differences in diagnostic practices, reporting systems, healthcare infrastructure, and access to specialists create inconsistencies in epidemiological reporting across countries.

Technology and Segment Insights

By Disease Type

Episodic cluster headache represents the largest patient segment because it accounts for the majority of diagnosed cases worldwide.

Chronic cluster headache represents a smaller but clinically significant population with greater disease burden, higher healthcare utilization, and increased treatment requirements.

By Age Group

Adults account for the largest patient population because cluster headache most commonly develops between early adulthood and middle age.

Although less common, pediatric and elderly cases continue to receive greater clinical attention as diagnostic awareness improves.

By Gender

Male patients continue to represent the majority of diagnosed cluster headache cases, although recent studies suggest the historical gender gap is gradually narrowing due to improved recognition among female patients.

By End User

Pharmaceutical companies remain the largest users of epidemiological analysis for patient segmentation, commercial forecasting, and clinical trial planning.

Healthcare providers utilize epidemiological data to optimize diagnosis, treatment planning, and healthcare resource allocation.

Academic institutions, government agencies, contract research organizations, and healthcare consulting firms also rely extensively on epidemiological intelligence to support research and healthcare policy development.

Regional Insights

North America dominates the global cluster headache epidemiology analysis market due to advanced healthcare infrastructure, comprehensive electronic health record systems, established neurological research programs, and high diagnostic awareness. The United States continues to lead epidemiological surveillance through extensive clinical research and real-world healthcare databases.

Europe represents another major market supported by strong academic collaboration, national disease registries, specialized headache centers, and comprehensive healthcare systems. Countries including Germany, the United Kingdom, France, Italy, Spain, and the Nordic nations continue to contribute significantly to epidemiological research.

Asia Pacific is expected to witness the fastest growth during the forecast period owing to expanding healthcare infrastructure, increasing neurological research, improving physician awareness, and greater investment in rare disease diagnosis across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually strengthening epidemiological surveillance through healthcare modernization, expanding specialist services, and increased participation in multinational neurological research programs.

Competitive and Strategic Outlook

The global cluster headache epidemiology analysis market includes epidemiology research organizations, healthcare analytics companies, pharmaceutical consulting firms, contract research organizations, and real-world evidence providers. Competition increasingly focuses on delivering accurate prevalence estimates, demographic segmentation, disease burden analysis, healthcare utilization studies, and predictive epidemiological models that support pharmaceutical development and healthcare planning.

Organizations continue investing in artificial intelligence, predictive analytics, electronic health record integration, and longitudinal patient databases to improve epidemiological accuracy. Strategic collaborations among pharmaceutical companies, academic institutions, healthcare providers, and public health agencies continue to strengthen data quality and analytical capabilities while supporting development of innovative therapies for cluster headache.

Future market development is expected to emphasize precision epidemiology, digital health integration, real-world evidence generation, and advanced forecasting models capable of supporting personalized medicine, healthcare policy, and commercial decision-making.

Conclusion

The global cluster headache epidemiology analysis market is expected to experience steady growth as disease awareness, diagnostic accuracy, and neurological research continue to improve worldwide. Increasing investment in rare neurological disorders, expanding healthcare databases, advances in epidemiological analytics, and growing pharmaceutical interest in innovative therapies are expected to support sustained demand for comprehensive patient population intelligence. Although challenges related to underdiagnosis, limited epidemiological data, and regional variability remain, continued advances in healthcare analytics and real-world evidence will strengthen understanding of cluster headache disease burden and support strategic decision-making across healthcare and pharmaceutical industries.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Overview
  • 1.1.1 Definition of Cluster Headache
  • 1.1.2 Scope of Epidemiology Assessment
  • 1.1.3 Study Objectives
  • 1.1.4 Key Findings
• 1.2 Key Epidemiology Insights
  • 1.2.1 Global Incidence Overview
  • 1.2.2 Global Prevalence Overview
  • 1.2.3 Episodic versus Chronic Cluster Headache Burden
  • 1.2.4 Gender-Based Epidemiology Trends
  • 1.2.5 Age-Specific Disease Distribution
  • 1.2.6 Major Epidemiological Trends and Future Outlook
• 1.3 Key Strategic Takeaways

2. Disease & Epidemiology Analysis

• 2.1 Disease Overview
  • 2.1.1 Definition and Diagnostic Criteria
  • 2.1.2 Disease History and Evolution of Classification
  • 2.1.3 Pathophysiology
  • 2.1.4 Neurobiological Mechanisms
  • 2.1.5 Disease Burden and Quality of Life Impact
• 2.2 Etiology and Risk Factors
  • 2.2.1 Genetic Factors
  • 2.2.2 Environmental Factors
  • 2.2.3 Smoking and Lifestyle Associations
  • 2.2.4 Comorbidities
• 2.3 Disease Classification
  • 2.3.1 Episodic Cluster Headache
  • 2.3.2 Chronic Cluster Headache
  • 2.3.3 Primary versus Secondary Cluster Headache
• 2.4 Diagnostic Landscape
  • 2.4.1 Diagnostic Criteria Based on International Classification of Headache Disorders
  • 2.4.2 Differential Diagnosis
  • 2.4.3 Imaging and Laboratory Investigations
  • 2.4.4 Diagnostic Challenges and Delays
• 2.5 Global Epidemiology Analysis
  • 2.5.1 Global Incidence
  • 2.5.2 Global Prevalence
  • 2.5.3 Diagnosed Prevalence
  • 2.5.4 Treated Population
  • 2.5.5 Epidemiology by Age Group
  • 2.5.6 Epidemiology by Gender
  • 2.5.7 Epidemiology by Disease Type
    • 2.5.7.1 Episodic Cluster Headache
    • 2.5.7.2 Chronic Cluster Headache
• 2.6 Epidemiology Forecast

3. Market Dynamics

• 3.1 Introduction
• 3.2 Market Drivers
  • 3.2.1 Rising Disease Awareness
  • 3.2.2 Increasing Diagnosis Rates
  • 3.2.3 Growing Availability of Targeted Therapies
  • 3.2.4 Advancements in Neuromodulation Technologies
• 3.3 Market Restraints
  • 3.3.1 Underdiagnosis and Misdiagnosis
  • 3.3.2 Limited Approved Therapies
  • 3.3.3 High Treatment Costs
  • 3.3.4 Reimbursement Challenges
• 3.4 Market Opportunities
  • 3.4.1 CGRP-Targeted Therapies
  • 3.4.2 Neuromodulation Devices
  • 3.4.3 Personalized Medicine Approaches
  • 3.4.4 Emerging Markets Expansion
• 3.5 Porter's Five Forces Analysis
• 3.6 PESTLE Analysis

4. Commercial & Market Access

• 4.1 Treatment Access Landscape
• 4.2 Pricing Analysis
• 4.3 Reimbursement Environment
• 4.4 Healthcare Expenditure Trends
• 4.5 Patient Assistance and Access Programs

5. Innovation & Pipeline Landscape

• 5.1 Innovation Trends
• 5.2 Emerging Drug Classes
  • 5.2.1 CGRP Monoclonal Antibodies
  • 5.2.2 Small Molecule CGRP Antagonists
  • 5.2.3 Neuromodulators
  • 5.2.4 Biologics and Novel Targets
• 5.3 Pipeline Analysis by Development Stage
  • 5.3.1 Preclinical
  • 5.3.2 Phase I
  • 5.3.3 Phase II
  • 5.3.4 Phase III
• 5.4 Pipeline Analysis by Mechanism of Action
• 5.5 Pipeline Analysis by Modality
  • 5.5.1 Small Molecules
  • 5.5.2 Monoclonal Antibodies
  • 5.5.3 Medical Devices
  • 5.5.4 Combination Therapies
• 5.6 Clinical Trial Landscape
  • 5.6.1 Ongoing Trials
  • 5.6.2 Completed Trials
  • 5.6.3 Trial Success Rates
  • 5.6.4 Key Trial Endpoints

6. Treatment Landscape

• 6.1 Current Treatment Algorithm
• 6.2 Acute Treatments
  • 6.2.1 Oxygen Therapy
  • 6.2.2 Triptans
    • 6.2.2.1 Sumatriptan
    • 6.2.2.2 Zolmitriptan
  • 6.2.3 Intranasal Therapies
• 6.3 Preventive Treatments
  • 6.3.1 Calcium Channel Blockers
  • 6.3.2 Corticosteroids
  • 6.3.3 Lithium
  • 6.3.4 CGRP Inhibitors
    • 6.3.4.1 Galcanezumab
• 6.4 Neuromodulation and Device-Based Therapies
  • 6.4.1 Non-invasive Vagus Nerve Stimulation
  • 6.4.2 Emerging Neuromodulation Technologies
• 6.5 Unmet Needs

7. Global Cluster Headache Epidemiology Report Size & Forecast

• 7.1 Global Market Size Analysis
• 7.2 Global Market Forecast
• 7.3 Market Forecast by Therapy Type
• 7.4 Market Forecast by Route of Administration
• 7.5 Market Forecast by Distribution Channel

8. Global Cluster Headache Epidemiology Report Segmentation

• 8.1 By Treatment Type
  • 8.1.1 Acute Treatment
  • 8.1.2 Preventive Treatment
  • 8.1.3 Bridge Treatments
• 8.2 By Drug Class
  • 8.2.1 Triptans
  • 8.2.2 CGRP Inhibitors
  • 8.2.3 Calcium Channel Blockers
  • 8.2.4 Corticosteroids
  • 8.2.5 Others
• 8.3 By Disease Type
  • 8.3.1 Episodic Cluster Headache
  • 8.3.2 Chronic Cluster Headache
• 8.4 By Route of Administration
  • 8.4.1 Injectable
  • 8.4.2 Oral
  • 8.4.3 Intranasal
• 8.5 By End User
  • 8.5.1 Hospitals
  • 8.5.2 Specialty Clinics
  • 8.5.3 Homecare Settings
  • 8.5.4 Others
• 8.6 By Distribution Channel
  • 8.6.1 Hospital Pharmacies
  • 8.6.2 Retail Pharmacies
  • 8.6.3 Online Pharmacies

9. Geographical Analysis

• 9.1 North America
  • 9.1.1 Epidemiology Overview
  • 9.1.2 Market Size and Growth
  • 9.1.3 Demand Drivers
  • 9.1.4 Regulatory Overview
  • 9.1.5 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Epidemiology Overview
  • 9.2.2 Market Size and Growth
  • 9.2.3 Demand Drivers
  • 9.2.4 Regulatory Overview
  • 9.2.5 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Epidemiology Overview
  • 9.3.2 Market Size and Growth
  • 9.3.3 Demand Drivers
  • 9.3.4 Regulatory Overview
  • 9.3.5 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Epidemiology Overview
  • 9.4.2 Market Size and Growth
  • 9.4.3 Demand Drivers
  • 9.4.4 Regulatory Overview
  • 9.4.5 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Epidemiology Overview
  • 9.5.2 Market Size and Growth
  • 9.5.3 Demand Drivers
  • 9.5.4 Regulatory Overview
  • 9.5.5 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

For each country:

Epidemiology Overview

Market Size and Forecast

Regulatory Framework

Reimbursement Scenario

Key Companies and Product Presence

11. Regulatory & Policy Landscape

• 11.1 Regulatory Overview
• 11.2 United States FDA Framework
• 11.3 European EMA Framework
• 11.4 Japan PMDA Framework
• 11.5 India CDSCO Framework
• 11.6 China NMPA Framework
• 11.7 Orphan Drug and Rare Disease Policies
• 11.8 Clinical Trial Regulations

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Approved Products Landscape
• 12.4 Pipeline Competitiveness
• 12.5 Strategic Collaborations
• 12.6 Licensing and Partnership Trends
• 12.7 Mergers and Acquisitions

13. Company Profiles

• 13.1 Eli Lilly and Company
  • 13.1.1 Company Overview
  • 13.1.2 Approved Product: Emgality (galcanezumab)
  • 13.1.3 Key Indications
  • 13.1.4 Pipeline and Clinical Development
  • 13.1.5 Strategic Initiatives
• 13.2 electroCore, Inc.
  • 13.2.1 Company Overview
  • 13.2.2 Approved Device: gammaCore
  • 13.2.3 Key Indications
  • 13.2.4 Pipeline and Innovation
  • 13.2.5 Strategic Initiatives
• 13.3 Pfizer Inc.
  • 13.3.1 Company Overview
  • 13.3.2 Approved Product: Imitrex (sumatriptan)
  • 13.3.3 Key Indications
  • 13.3.4 Pipeline Portfolio
  • 13.3.5 Strategic Initiatives
• 13.4 GlaxoSmithKline plc
  • 13.4.1 Company Overview
  • 13.4.2 Approved Product: Imigran (sumatriptan)
  • 13.4.3 Key Indications
  • 13.4.4 Pipeline Portfolio
  • 13.4.5 Strategic Initiatives
• 13.5 Medtronic plc
  • 13.5.1 Company Overview
  • 13.5.2 Product
  • 13.5.3 Key Indications
  • 13.5.4 Pipeline Portfolio
  • 13.5.5 Strategic Initiatives
• 13.6 Grunenthal GmbH
  • 13.6.1 Company Overview
  • 13.6.2 Approved Portfolio
  • 13.6.3 Key Indications
  • 13.6.4 Pipeline Portfolio
  • 13.6.5 Strategic Initiatives
• 13.7 Zosano Pharma Corp.
  • 13.7.1 Company Overview
  • 13.7.2 Approved Product
  • 13.7.3 Key Indications
  • 13.7.4 Pipeline Portfolio
  • 13.7.5 Strategic Initiatives
• 13.8 Bausch Health Companies Inc.
  • 13.8.1 Company Overview
  • 13.8.2 Approved Portfolio
  • 13.8.3 Key Indications
  • 13.8.4 Pipeline Portfolio
  • 13.8.5 Strategic Initiatives
• 13.9 Viatris Inc.
  • 13.9.1 Company Overview
  • 13.9.2 Generic Sumatriptan Portfolio
  • 13.9.3 Key Indications
  • 13.9.4 Pipeline Portfolio
  • 13.9.5 Strategic Initiatives
• 13.10 Autonomic Technologies Inc.
  • 13.10.1 Company Overview
  • 13.10.2 Product Portfolio
  • 13.10.3 Key Indications
  • 13.10.4 Pipeline Portfolio
  • 13.10.5 Strategic Initiatives

14. Future Outlook

• 14.1 Future Epidemiology Trends
• 14.2 Emerging Therapeutic Opportunities
• 14.3 Innovation Outlook
• 14.4 Competitive Evolution
• 14.5 Market Growth Scenario Through Forecast Period

15. Methodology

• 15.1 Research Methodology
• 15.2 Secondary Research Sources
• 15.3 Primary Research Approach
• 15.4 Epidemiology Modeling Framework
• 15.5 Market Estimation Methodology
• 15.6 Forecasting Assumptions
• 15.7 Data Validation and Quality Control
• 15.8 Limitations and Disclaimer